A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies
This Phase 3 trial, sponsored by The Canadian Blood and Marrow Transplant Group, investigates the efficacy of G-CSF mobilized peripheral blood stem cell transplantation compared to traditional bone marrow transplantation in patients with hematologic malignancies. The study's completion and its focus on critical endpoints such as time to treatment failure, overall survival, and quality of life could provide valuable data to support the commercialization of G-CSF products in hematologic therapies. The results may influence treatment protocols and market positioning for stem cell transplantation therapies, particularly in regions with high incidences of hematologic cancers. Companies involved in hematopoietic stem cell therapies should monitor these findings closely for potential shifts in standard care practices and competitive dynamics.
Indication: Chronic Myeloproliferative Disorders
Modality: protein therapy
Target: G-CSF (Granulocyte Colony-Stimulating Factor) mobilized stem cells for hematopoietic transplantation.
Sponsor: The Canadian Blood and Marrow Transplant Group
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: G-CSF (Granulocyte Colony-Stimulating Factor) mobilized stem cells for hematopoietic transplantation.
View original source fields
Condition raw: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Secondary Myelofibrosis
Condition normalized: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Secondary Myelofibrosis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: G-CSF (Granulocyte Colony-Stimulating Factor) mobilized stem cells for hematopoietic transplantation.
Target normalized: G-CSF (Granulocyte Colony-Stimulating Factor) mobilized stem cells for hematopoietic transplantation.